Last update: Jan. 10, 2015


Very Low Risk for breastfeeding

Not risky for breastfeeding or infant.

Excreted into breast milk in a non-significant amount with no side-effects observed in breastfed infants of treated mothers. The plasma levels in those infants have been undetectable or very low.

During the first 6 weeks after birth, non-hormonal methods are of choice as contraceptives.

If associated to estrogens may inhibit lactation. It is recommended the use of contraceptive medication that does not contain estrogens, or, better if it contains progestogen alone.


We do not have alternatives for Dioxipregnen since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Dioxipregnen is also known as Progesterone. Here it is a list of alternative known names::


Dioxipregnen belongs to these groups or families:


Main tradenames from several countries containing Dioxipregnen in its composition:


Variable Value Unit
Bioavailability Baja - Low %
Molecular weight 314 daltons
Protein Binding 99 %
Tmax 6 hours
T1/2 48 hours


  1. Berens P, Labbok M; Academy of Breastfeeding Medicine. ABM Clinical Protocol #13: Contraception During Breastfeeding, Revised 2015. Breastfeed Med. 2015 Abstract Full text (link to original source) Full text (in our servers)
  2. RamaRao S, Clark H, Merkatz R, Sussman H, Sitruk-Ware R. Progesterone vaginal ring: introducing a contraceptive to meet the needs of breastfeeding women. Contraception. 2013 Abstract
  3. Rowe H, Baker T, Hale TW. Maternal medication, drug use, and breastfeeding. Pediatr Clin North Am. 2013 Feb;60(1):275-94. Abstract
  4. Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention (CDC). U.S. Selected Practice Recommendations for Contraceptive Use, 2013: adapted from the World Health Organization selected practice recommendations for contraceptive use, 2nd edition. MMWR Recomm Rep. 2013 Abstract Full text (link to original source) Full text (in our servers)
  5. Amir LH, Pirotta MV, Raval M. Breastfeeding--evidence based guidelines for the use of medicines. Aust Fam Physician. 2011 Abstract Full text (link to original source) Full text (in our servers)
  6. Massai R, Quinteros E, Reyes MV, Caviedes R, Zepeda A, Montero JC, Croxatto HB. Extended use of a progesterone-releasing vaginal ring in nursing women: a phase II clinical trial. Contraception. 2005 Abstract
  7. Erkkola R, Landgren BM. Role of progestins in contraception. Acta Obstet Gynecol Scand. 2005 Abstract
  8. Johansson ED, Sitruk-Ware R. New delivery systems in contraception: vaginal rings. Am J Obstet Gynecol. 2004 Abstract
  9. Gjerdingen D. The effectiveness of various postpartum depression treatments and the impact of antidepressant drugs on nursing infants. J Am Board Fam Pract. 2003 Abstract Full text (link to original source) Full text (in our servers)
  10. Halderman LD, Nelson AL. Impact of early postpartum administration of progestin-only hormonal contraceptives compared with nonhormonal contraceptives on short-term breast-feeding patterns. Am J Obstet Gynecol. 2002 Abstract
  11. Baheiraei A, Ardsetani N, Ghazizadeh S. Effects of progestogen-only contraceptives on breast-feeding and infant growth. Int J Gynaecol Obstet. 2001 Abstract
  12. AAP - American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001 Sep;108(3):776-89. Abstract Full text (link to original source) Full text (in our servers)
  13. Massai R, Miranda P, Valdés P, Lavín P, Zepeda A, Casado ME, Silva MA, Fetis G, Bravo C, Chandía O, Peralta O, Croxatto HB, Díaz S. Preregistration study on the safety and contraceptive efficacy of a progesterone-releasing vaginal ring in Chilean nursing women. Contraception. 1999 Abstract
  14. Chen JH, Wu SC, Shao WQ, Zou MH, Hu J, Cong L, Miao L, Wang C, Dong J, Gao J, Xiao BL. The comparative trial of TCu 380A IUD and progesterone-releasing vaginal ring used by lactating women. Contraception. 1998 Abstract
  15. Díaz S, Zepeda A, Maturana X, Reyes MV, Miranda P, Casado ME, Peralta O, Croxatto HB. Fertility regulation in nursing women. IX. Contraceptive performance, duration of lactation, infant growth, and bleeding patterns during use of progesterone vaginal rings, progestin-only pills, Norplant implants, and Copper T 380-A intrauterine devices. Contraception. 1997 Abstract
  16. Sivin I, Díaz S, Croxatto HB, Miranda P, Shaaban M, Sayed EH, Xiao B, Wu SC, Du M, Alvarez F, Brache V, Basnayake S, McCarthy T, Lacarra M, Mishell DR Jr, Koetsawang S, Stern J, Jackanicz T. Contraceptives for lactating women: a comparative trial of a progesterone-releasing vaginal ring and the copper T 380A IUD. Contraception. 1997 Abstract
  17. Kelsey JJ. Hormonal contraception and lactation. J Hum Lact. 1996 Abstract
  18. [No authors listed] Progestogen-only contraceptives during lactation: II. Infant development. World Health Organization, Task Force for Epidemiological Research on Reproductive Health; Special Programme of Research, Development, and Research Training in Human Reproduction. Contraception. 1994 Abstract
  19. Shaaban MM. Contraception with progestogens and progesterone during lactation. J Steroid Biochem Mol Biol. 1991 Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at

e-lactancia is a resource recommended by IHAN from Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM